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The extracellular domain of the  rabbit growth hor- 
mone (GH) receptor has previously  been  shown to be 
associated with the nucleus.  However, in  this pecies the 
GH binding protein (BP) is derived by proteolytic cleav- 
age of the full-length receptor, and thus distinction be- 
tween the receptor and BP  is  difficult.  The intracellular 
domain of the GH receptor is required for GH -8 t' 1mu- 
lated function. Thus a direct nuclear function of GH 
would  presumably require  the receptor intracellular do- 
main in  the nucleus. We have therefore characterized 
the rat nuclear GH receptor and BP  based  on their dis- 
tinct antigenic identity. We show, in uiuo, that  the full- 
length receptor is associated with the nucleus, including 
the respective subnuclear fractions (nucleoplasm, outer 
nuclear membranes, inner nuclear membranes, and 
chromatin). In uiuo, the receptor is also subject to li- 
gand-dependent nuclear translocation. 
Cellular transfection of rat GH receptor cDNA re- 
sulted in  the appearance of nuclear binding sites for 
1261-labeled human GH not present in  the untransfected 
parental cell line (Chinese hamster ovary (CHO),  buffalo 
rat liver). To determine which portion of the receptor 
was responsible for nuclear anchorage, we examined 
the binding of '261-labeled  human GH to whole nuclei 
isolated from CHO cells expressing the full-length recep- 
tor, a receptor in which 184 amino acids had been de- 
leted from the carboxyl-terminal intracellular domain 
(CHO-454) and a receptor containing only 5 of  349 amino 
acids in the intracellular domain (CHO-294). Nuclear 
binding above the level of the untransfected parental 
cell line was detected only in CHO-638 and CHO-454 
cells, suggesting that amino acids 294454 of the recep- 
tor  are necessary for nuclear anchorage.  This observa- 
tion was not due to membrane contamination, as the 
CHO-294 cells express a membrane-bound receptor that 
was not anchored in  the nucleus. The full-length GH 
receptor in receptor cDNA-transfected  cells is nucleocy- 
toplasmic in  the absence of ligand but is also subject to 
rapid ligand-dependent nuclear translocation. The pres- 
ence of the  intracellular domain of the GH receptor in 
the nucleus allows the possibility of a direct nuclear 
response to GH. 
The  growth hormone receptor  is a member of the cytokine 
receptor  superfamily (1-4). In  the  rat,  the GH1 receptor  is  but 
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one of two growth hormone binding moieties  (5). The second is 
derived by alternate splicing of the growth  hormone  receptor 
gene at   the  7-8th exon boundary  and is termed  the GH binding 
protein  (GHBP) (3, 5). The GH receptor and  not  the  GHBP is 
the  active moiety in  GH  signal  transduction (61, presumably 
through  interaction  with associated kinases  such as JAK-2 (71, 
which requires  the presence of the  receptor  intracellular do- 
main (8). However, the promiscuity of such  kinase associations 
does not  lend specificity to polypeptide-induced transcriptional 
events even if necessary for signal  transduction.  This specific- 
ity  may  be provided by the  nuclear association of respective 
receptor molecules in a manner analogous to  steroid hormone- 
induced transcription  where  the receptor is  an  integral compo- 
nent of the  transcription complex (9). Indeed, receptors for mul- 
tiple polypeptide ligands have been reported to be nuclear 
associated including  insulin (lo), prolactin (ll), angiotensin I1 
(121, epidermal growth factor, nerve growth factor, platelet- 
derived growth factor  (13,141, and fibroblast growth factor (15). 
In some cases,  ligands for these receptors have been demon- 
strated  to  induce  nuclear RNA synthesis  without cytoplasmic 
involment (16). Furthermore,  many  kinases  apparently  central 
to signal  transduction  are  nuclear (associated with or translo- 
cate  to  the  nucleus  when  activated (17, 18)), and  nuclear  trans- 
location of the  insulin  (19,201  and  epidermal  growth  factor  (21) 
receptors has been  reported. 
I t  has been demonstrated previously by us (22-24) and 
others  (25)  that  the  GH  receptorBP  and  GHBP  are associated 
with  the nucleus. The previous characterization of the  nuclear 
GH  receptorBP  was performed in  the  rabbit (23). In this spe- 
cies, the  GHBP is derived  from  proteolytic  cleavage of the  re- 
ceptor (26, 27), and  thus  distinction  between  the receptor and 
BP is difficult. Although our affinity  cross-linking studies 
showed that  the  rabbit  liver  chromatin  binding  subunit  had  
M, similar  to that of the  BP (Mr,  67,000 versus 60,000), it was 
not possible to be categoric about  the  absence of full-length 
receptor owing to likely  receptor  proteolysis. Indeed, both Tri- 
ton X-100-solubilized inner  and  outer  nuclear  membranes from 
rabbit liver-contained polyethylene glycol 6,000-precipitable 
GH  binding activity indicative of full-length receptor (23). We 
have  also  shown  that  the cytoplasmic  domain of the  GH recep- 
tor is required for nuclear translocation of growth hormone 
(28). 
If nuclear  growth hormone binding  activity  is  to be of func- 
tional  importance,  the presence of the  intracellular domain of 
the receptor in  the  nucleus is likely to be necessary. We have 
therefore  characterized  the  rat  nuclear  GH receptor and bind- 
tein; h, human; 0, ovine; r, rat; b, bovine; mAb, monoclonal antibody; 
PEG, polyethylene glycol; M A P ,  mitogen-activated  protein; PRL, pro- 
lactin; NLS, nuclear localization sequence; CHO, Chinese hamster 
ovary. 
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ing protein on the basis of their distinct antigenic identities. We 
show here that  the full-length receptor is associated with the 
nucleus, that  the intracellular domain of the receptor is re- 
quired for nuclear anchorage, and that  the receptor is translo- 
cated to the nucleus in a ligand-dependent manner. 
EXPERIMENTAL PROCEDURES 
Materials-Disuccinimidyl suberate was purchased from Pierce. 14C- 
Methylated protein molecular  weight markers, lZ6I, goat antirabbit im- 
munoglobulin G, horseradish peroxidase-conjugated F(ab), fragment, 
biotin-streptavidin-biotin horseradish peroxidase  complex and  the ECL 
kit were purchased from Amersham (United Kingdom). Rabbit anti- 
mouse immunoglobulins were purchased from Dakopatts (Denmark). 
Reagents for  cell culture were purchased from  Life  Technologies, Inc. 
Recombinant human (h) GH was a gift from Pharmacia (Stockholm, 
Sweden). Recombinant  bGH was a gift  from  Monsanto Co. (St. Louis, 
MO).  Ovine (0) PRL (S-16), rat  (r) PRL (B-3), and rGH  (1-4)  were gifts 
from the National Hormone and Pituitary Agency (Baltimore, MD). 
Aminoacetonitrile hydrochloride, benzamidine hydrochloride, 3'-3'-dia- 
minobenzidine  hydrochloride, protein G-Sepharose, and aprotinin were 
purchased from Sigma. Recombinant human GHBP was a generous gift 
of Novo-Nordisk (Danmark), and recombinant rat GHBP was a gener- 
ous gift of Dr. W. R. Baumbach (American Cyanamid). 
GH  Receptor and GHBP  Monoclonal  Antibody  Production-mAb  4.3 
(a generous gift of Dr.  W.R. Baumbach) was raised against a synthetic 
peptide corresponding to the predicted 17-amino  acid hydrophilic car- 
boxyl terminus of the rat GHBP mRNA (CGPKFNSQHPHQEIDNHL) 
(29). It specifically  recognizes recombinant rat GHBP  produced in bac- 
teria  and immunoprecipitates GH binding activity from rat and mouse 
serum (29). mAb 4.3 does not recognize the  rat GH receptor as deter- 
mined by Western blot analysis. mAb  263 was raised using as immuno- 
gen-purified microsomal rat and rabbit GH receptor and reacts specif- 
ically against GH receptoriBP in immunoblot analysis (1, 30). Under 
certain conditions it precipitates rat and rabbit GH receptor, but it can 
also compete  for  hormone binding to subtypes of the GH receptor. mAb 
263 also precipitates GHBP  from serum and cytosol (31). mAb 43 was 
raised using as immunogen-purified microsomal rabbit GH receptor 
(32). mAbs 7 and 50.8 were used as control antibodies (32). mAb 7 
recognizes a species-specific epitope on the rabbit GH receptor. mAb 
50.8 is  a noncross-reactive murine mAb  of the same isotype as mAb  263 
raised against Brucella abortus (32). 
Production of Polyclonal Antiserum to GH Receptor Intracellular 
Domuin-A pGEX fusion protein was produced by ligating an Ssp1 
fragment of the rabbit GH receptor cDNA into the pGEX-2T plasmid 
(33). This resulted in expression of glutathione S-transferase fused to 
the entire  rabbit GH receptor cytoplasmic  region.  After  expression and 
purification on glutathione-agarose, 200 pg of the fusion protein in 
Freund's complete adjuvant was injected into the foot pad lymph nodes 
of Agouti rabbits. This was followed  by injection of the same amount of 
antigen at 2-week intervals, first into the popliteal nodes and then 
subcutaneously at 6  sites  in  the back and finally by intravenous injec- 
tion of 100 pg a week  before  sacrifice. Using a second antibody separa- 
tion (32), 100  pl of the serum chosen  for the present study was able to 
immunoprecipitate 50% of lZ5I-hGH-receptor complexes  from  25 pg of 
solubilized female rabbit liver microsomes at a final dilution of l:104. 
This antiserum was unable to precipitate rabbit mammary gland IZ5I- 
hGH-prolactin receptor complexes. 
Immunoblotting with  Polyclonal Antiserum to the  GH  Receptor In- 
tracellular Domain-Subcellular fractions for these studies were pre- 
pared as described previously (23) except for the addition of 10 m~ 
benzamidine hydrochloride to  all buffers.  Only high quality prepara- 
tions (as assessed by morphology after toluidine blue staining) were 
used for these studies. Adult male New Zealand  White rabbits were 
injected into the ear vein with either saline or 1 mg of recombinant bGH 
and then sacrificed by cervical  dislocation 10 min after injection. After 
preparation of purified nuclear fractions, Bradford protein determina- 
tions (34) were undertaken for  gel loading normalization. Membrane, 
nuclear, or chromatin fractions then were  loaded  onto a 7.5% acrylam- 
ide gel  (37.5:1, acrylamidehis) according  to  Laemmli (35). Proteins were 
transferred to  nitrocellulose membranes (Schleicher & Schuell BA 83) 
using a semi-dry apparatus (3 h at 130 m A )  in Laemmli electrophoresis 
buffer containing 20% methanol. Membranes were  blocked  for  30  min 
with 5%  milk  powder in 20 mM Tris-HC1,150 mM NaC1,  0.1% "ween 20, 
pH  7.4 (wash buffer), and then agitated for  90 min at  20  "C with either 
preimmune rabbit serum or polyclonal antibody at 1:300 in blocking 
solution. After 4 x 5-min washes in wash buffer, membranes were agi- 
tated with donkey anti-rabbit Ig, horseradish peroxidase-conjugated 
F(ab), fragment in blocking  buffer  for 1 h at 20  "C. After a  further four 
washes in wash buffer, receptor was revealed with the ECL kit. 
GH  Receptor and GHBP cDNA Dunsfection-Rat GH receptor and 
GHBP cDNAs were  cloned into an expression plasmid containing an 
SV40 enhancer and  a metallothionein promoter. The cDNAs were trans- 
fected into CHO-K1  cells with lipofectin together with the pIPB-1 plas- 
mid,  which contains the neomycin resistance gene  fused  to the thymi- 
dine kinase promoter (Table I). Stable integrants were  selected using 
1,000  pg/ml  G418. The complete GH receptor cDNA(2)  coding  for amino 
acids 1-638 was expressed in  CH04-638 cells (6). By in vitro mutagen- 
esis of GH receptor, cDNA stop codons were created at position  295 
(expressed in CHO-294  cells) and at position  455 (expressed in CHO- 
454 cells) (6). The GHBP  cDNA consists of the extracellular portion of 
the receptor cDNA (corresponding to amino acids (1-262) fused to a 
specific hydrophilic carboxyl terminus coding for 17 amino acids (5). 
GHBP  was expressed in CHO-BP2  cells (6). BRL cells  were transfected 
with the complete GH receptor cDNA inserted in  an expression  vector 
containing the  human cytomegalovirus enhancer and promoter 
(pcDNAl) (36). 
Immunohistochemistry-Sections  were deparafinized  and subjected 
to immunohistochemical staining according to Ref.  22.  ICAb was used 
at 16 pg/ml to  achieve maximal specific staining. Controls were per- 
formed by (a) omission of the primary antibody; (b) replacing ICAb with 
the same protein concentration of preimmune rabbit serum; and ( c )  
preincubation (24 h at  4 "C) of  ICAb with either 20 pg/ml recombinant 
receptor intracellular domain protein, glutathione S-transferase, or re- 
combinant rat GHBP  before application to the sections. 
Cell  Culture-CHO cells  were  grown to confluence in 800-ml culture 
flasks in Ham's  F-12  medium supplemented with 10% fetal calf serum, 
50 unitdm1 penicillin, and 50 pg/ml streptomycin. Confluent cells  were 
incubated in serum-free medium  for 12 h before  removal with a rubber 
policeman and purification of nuclei as described below.  BRL cells  were 
cultured in Dulbecco's modified Eagle's medium supplemented with 
10% fetal calf serum, 50 unitdm1 penicillin, and 50  pg/ml streptomycin 
and treated similarly before nuclear purification. For immunocyto- 
chemistry,  cells  were  grown on coverslips in six-well dishes. Fixation 
was performed with phosphate-buffered saline, pH 7.4, containing 4% 
paraformaldehyde for 10 min at room temperature. Cells  were stored in 
70% ethanol until processing.  Cells  were  permeabilized with phosphate- 
buffered saline, 0.1% Triton X-100 and processed  for  immunocytochem- 
istry as described  above. Human GH at a final concentration of 100 n~ 
was used to determine the effect of  GH on the intracellular distribution 
of the GH receptor in cells that had been incubated for 12 h  in serum- 
free media. 
DNA and Protein Estimation-DNA concentration was estimated by 
the method of Labarca and Paigen (37) using Hoechst  33528. Protein 
concentration was estimated by the method of  Lowry  et al. (38) after 
alkaline solubilization of particulate fractions. 
Iodination of Hormone-hGH was iodinated by the Iodogen  method 
(39) and fractionated on a Sepharose G-25  column.  Specific activity was 
80-153  pCi/pg. 
Nuclear Fraction Preparation-Adult (10-12 week)  female rat liver 
nuclei  were prepared by a modification (23, 40) of the method of  Wang 
(41) using 0.1% Triton X-100 in all buffers. Livers were  homogenized in 
3 volumes of homogenization  buffer (25 mM Tris-HC1,  0.1% Triton X-100, 
0.32 M sucrose, 3 mM MgCl,, 2 rn EGTA, 0.1 mM spermine, 2 mM 
phenylmethylsulfonyl  fluoride, 10 mM benzamidine hydrochloride, 3 rn 
aminoacetonitrile hydrochloride, pH 7.4).  After the low speed spin in 0.2 
M sucrose, the crude nuclear pellet was resuspended in  a final sucrose 
concentration of 55% and centrifuged at 60,000 x g for  60  min at 4 "C. 
Whole nuclei  were prepared by washing the 55% sucrose nuclear pellet 
with 0.4%  Nonidet  P-40 as described  previously by us (23). Four nuclear 
fractions were  also prepared after  the sucrose gradient centrifugation. 
Homogenization of the nuclear pellet in homogenization  buffer without 
Triton X-100 yielded  nucleoplasm and soluble material released from 
the nuclear sac. Nucleoplasm was separated from particulate material 
by centrifugation at 150,000 x g for 60 min. Previous studies have 
demonstrated differential solubilization of outer and inner nuclear 
membranes with 1 and 2% Triton X-100 respectively. The residual 2% 
Triton  X-100-insoluble material constitutes chromatin. Solubilization of 
the inner  and outer nuclear membranes was performed by  homogeni- 
zation and stirring for 15 min at room temperature with the appropriate 
Triton X-100 concentration before centrifugation at 150,000 x g for  60 
min at 4 "C. Nuclear fractions were prepared in 1:2 volumedoriginal 
liver weight. Nuclear preparations were routinely assessed for  mem- 
brane contamination. The 1% Triton X-100-solubilized outer nuclear 
membranes were contaminated by the microsomal fraction, but  this is 
not surprising as  the outer nuclear membrane is contiguous with the 
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endoplasmic reticulum (42). Other nuclear preparations (Nonidet P-40- 
washed) and fractions (nucleoplasm, 2% Triton X-100-solubilized inner 
nuclear membranes and chromatin) had no detectable NADPH-cyto- 
chrome c reductase activity (43) and had no contamination visible by 
light or electron microscopy. 
Scatchard Analysis of lZ5I-hGH Binding-Assays  were  performed in 
triplicate in 12 x 75-mm borosilicate tubes according to Waters and 
Friesen (44). Displacing ligands were diluted in radioreceptor assay 
buffer  (RRA:  50 m~ Tris-HC1, 10 mM MgCl,, 0.1%  bovine serum albu- 
min, pH  7.4).  Total incubation volume  was  0.5  ml consisting of 100 pl of 
RRA, 100 p1  of appropriate nuclear fraction, 100 pl of displacing ligand 
or 100 pl RRA, and 100 1.11  of lZ5I-hGH (approximately 150,000 cpm/ 
tube). The assays were incubated on an agitating platform for  12-16 h 
at  4 "C. Assays  were terminated by the addition of 3 ml of RRA and 
centrifugation for 30 min at  1,600 x g (4 "C). Supernatants were re- 
moved, and the pellet was counted on an LKB 1274 y spectrometer. 
Scatchard analysis (45) was performed with the LIGAND program (46). 
Immunoprecipitation of GH Receptor and GHBP-Titration of pre- 
cipitating mAbs (mAb 4.3, 43, 263) against lZ5I-hGH.GH receptoriBP 
complexes in 1% Triton X-100 solubilized  microsomes,  nucleoplasm, 1% 
Triton X-100 solubilized outer nuclear membranes or 2% solubilized 
inner nuclear membranes was performed by the standard double anti- 
body method as described  previously  (23,  31). Precipitation of the full- 
length receptor was similarly performed with ICAb except that protein 
G-Sepharose was used to separate  ternary complexes (50 pl of protein G 
and incubation for  90 min at 4 "C). In  all instances either  a mAb  of the 
same isotype (mAb  7, IgGkl) was used as control  for mAbs 4.3,43, and 
263,  or ammonium sulfate-precipitated preimmune rabbit serum was 
used as a control  for  ICAb. 
Affinity Cross-link to Chromatin Receptor-The 2% Triton X-100- 
insoluble chromatin fraction was washed in 100  volumes of cross-link 
buffer  (50 m~ Hepes-NaOH, pH  7.5,  10 m~ MgCl,, 1 mM PMSF, 3 mM 
aminoacetonitrile, and 10 mM benzamidine). Resuspended chromatin 
was then subject to  radioreceptor assay (with excess  hGH, bGH, and 
rPRL  each at 10 pdml) as above but with cross-link buffer rather  than 
RRA buffer. After 16 h of agitation at 4 "C, 3 ml  of  cold cross-link buffer 
was added, and chromatin was pelleted by centrifugation at 1,600 x g 
for  30  min at 4 "C. The supernatant containing unbound lZ5I-hGH was 
removed, and  the pellet was resuspended in 0.5 ml  of cross-link buffer. 
Cross-linking was performed by the addition of 25 pl of 10 m~ disuc- 
cinimidyl suberate  in dimethyl sulfoxide with vortexing and was ter- 
minated a h r  15 min at 4 "C with 20 pl of 1 M Tris-HC1,  pH  7.5. Chro- 
matin was pelleted, excess  buffer was removed, and the pellets were 
solubilized in SDS-PAGE sample buffer with dithiothreitol and electro- 
phoresed on a 9% acrylamide gel (35). Gels  were dried and autoradio- 
graphed with Kodak AR5 film in  an x-ray cassette with intensifylng 
screens at -85  "C. 
RESULTS 
Hormone Binding to Rat Liver Nuclei and Nuclear 
Fractions-To demonstrate  the presence of somatogenic bind- 
ing  sites  in rat liver  nuclei, we isolated whole Nonidet P-40- 
washed  nuclei as described previously (23). Specific high afin- 
ity (KO = 1.1 f 0.4 x lo9 M - ~ )  binding of lZSI-hGH  displaceable by 
both hGH and purely somatogenic ligands (bGH, rGH) was 
detected  (Fig. 1A). Thus  the GH receptor/BP is present  in rat 
liver  nuclei as previously reported by immunohistochemistry 
(22-24). To further  characterize  the  nuclear  GH receptor in rat 
liver  nuclei, we prepared different nuclear fractions. A soluble 
fraction was formed upon homogenization of intact nuclei and 
constituted nucleoplasm and soluble material released from 
the  nuclear sac. The  outer  and  inner  nuclear  membranes were 
differentially solubilized with 1 and 2% Triton X-100, respec- 
tively, and  the  residual 2% Triton X-100-insoluble material con- 
stituted  chromatin. Somatogenic-specific binding was  detected 
in all fractions. Binding  was both saturable  and time-depend- 
ent (Fig. lB ). Approximately  64% of GH binding activity pres- 
ent  in nucleoplasm was precipitable with  PEG 6,000 alone as 
compared with PEG 6,000-precipitable specific binding with 
the addition of precipitating mAb 263. In 1 and 2% Triton 
X-100-solubilized outer  and  inner  nuclear  membranes,  25  and 
78%, respectively, of specific GH binding  activity was precipi- 
table with PEG 6,000 alone. Within the nucleus differential 
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FIG.  1. Hormone competition analysis of '=I-hGH binding to 
whole Nonidet P-40-washed nuclei and chromatin isolated from 
female rat  liver. A, hormone  competition curve of '=I-hGH binding to 
female rat liver nuclei.  Displacing ligands were  hGH and bGH.  Nuclei 
were assayed at  a final DNAconcentration of  40-70  pg  of DNNml. Total 
added radioactivity was 140,000 cpdtube. Specific and nonspecific 
binding was 8.7 and 4.5%,  respectively. The specific activity of  "'I-hGH 
was 152  pCUpg  of protein. The K, from three such determinations with 
bGH as displacing ligand was 1.1 -c 0.4 x lo9 M-'. B, time course of 
lZ5I-hGH binding to female rat liver chromatin with bGH as displacing 
ligand. Points represent means of triplicate determinations with stand- 
ard deviation indicated. Chromatin was assayed at  a final DNA  concen- 
tration of 40  pg  DNA. Incubation was performed at 4 "C  on an agitating 
platform. 
TA~LE I 
Binding characteristics of cells stably transfected  with full-length or 
truncated forms of rat GH receptor  cDNA and the  GHBP 
The affinity of hGH for the expressed GH-binding proteins and 
capacity were calculated from Scatchard analysis of lz6I-hGH binding 
with hGH as displacing ligand as described previously (6). ND, not 
detectable under these assay conditions. 















Expressed as fmoVpg  of protein in  the media. 
partitioning of GH binding  activity was observed. Based on the 
percentage of total  nuclear GH receptoriBP content,  the major- 
ity of GH binding was  present  in  the  outer  nuclear  membrane 
(37%) followed  by the  inner  nuclear  membrane (31%), chroma- 
tin (20%), and nucleoplasm (12%) (see Fig. 6A). 
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FIG. 2. Immunoprecipitation of GH receptor and GHBP f rom 
1% Triton X-100-solubilized  microsomal fraction of female rat 
liver. The  ordinates show the antibody  precipitable  binding as a per- 
centage of the maximum  precipitable specific binding for each  protein 
species. Points  represent  mean of triplicate  determinations. A, precipi- 
tation of GHBP  with a monoclonal antibody  (mAb 4.3) directed  against 
a  synthetic  peptide  corresponding  to  the  unique  17-amino acid hydro- 
philic  tail. Bound and  free  hormone  were  separated  using  the  double 
antibody  method as described. Total added  radioactivity  was 160,000 
cpdtube. Specific and nonspecific binding  were 2.7 and 3.9%, respec- 
tively, of total  radioactivity  added. B, precipitation of GH receptor  with 
polyclonal antisera  directed  against  recombinant  intracellular  domain 
protein.  Separation of bound and  free  hormone  were  achieved  using 
protein  G-Sepharose. Total added  radioactivity  was 118,000 cpdtube. 
Specific and nonspecific binding  were 1.2 and 2.9%, respectively, of total 
radioactivity  added. 
Characterization of ZCAb and Precipitation of GH Receptor 
and  GHBP from Solubilized Rat Liver Microsomal 
Fraction-We wished to  establish methodology to  enable dis- 
tinction between the GH receptor and  the GHBP in soluble 
fractions of rat liver and rat liver nuclei. Thus  it  was necessary 
to  raise  antisera  against  the  intracellular domain of the  GH 
receptor. Serum  was collected from rabbits immunized with  the 
recombinant  receptor intracellular domain glutathione 
S-transferase fusion  protein, ammonium sulfate-precipitated, 
and used to precipitate GH binding activity from 1% Triton 
X-100-solubilized rat liver microsomal fraction. Specific bGH- 
displaced '251-hGH binding  was precipitated in  high titre with 
serum  termed ICAb (Fig. 2 B ) .  This specific binding was com- 
peted by the presence of excess receptor intracellular domain 
but not by the  glutathione  S-transferase portion of the fusion 
protein. The GHBP has also  been reported  to associate with  the 
microsomal fraction (59). To verify this, we immunoprecipitated 
GHBP from the 1% Triton X-100-solubilized microsomal frac- 
tion with mAb 4.3 (directed against carboxyl-terminal hydro- 
philic tail of GHBP) (Fig. 2 A ) .  
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FIG. 3. Western blot analysis of GH receptor intracellular do- 
main. Western blot analysis with ICAb was performed as described 
under "Experimental Procedures." Rat and rabbit liver microsomal, 
nuclear, and chromatin fractions were prepared as described under 
"Experimental Procedures." GH  injection of animals (1 mg of recombi- 
nant bGH for rabbit)  was  performed  via  the  intravenous  route. Equiv- 
alent  amounts of protein  were  loaded for each  comparative  lane. Top, 
Western blot analysis of rabbit GH receptor  intracellular  domain. Lane 
1, hepatic microsomal fraction from non-GH-injected female  rabbit; lune 
2, hepatic  nuclear  fraction from non-GH-injected female  rabbit; lune 3, 
hepatic microsomal fraction from GH-injected female rabbit; lune 4, 
hepatic  nuclear  fraction from GH-injected female  rabbit; lune 5, hepatic 
chromatin  fraction from non-GH-injected female  rabbit; lune 6,  hepatic 
blot  analysis of rat GH  receptor  intracellular domain. Lune 1, hepatic 
chromatin  fraction from GH-injected female rabbit. Bottom, Western 
microsomal fraction from female rat; lune 2, hepatic  nuclear  fraction 
from female rat. Definitive  visualization of GH receptor  in  preparations 
of rat liver  with  more loaded protein  and  longer  exposure; lune 3, he- 
patic  nuclear  fraction from female  rat; lune 4, hepatic  chromatin  frac- 
tion  from  female rat. 
The  GH receptor exists as a 120-kDa protein in  the  rabbit 
and  rat (47). To determine  the molecular mass of the species 
recognized by ICAb, we performed Western blot analysis of 
rabbit  and rat liver microsomal fractions. In both instances a 
band  migrating  with M, of 120,000 was  identified  (Fig. 3). In 
the  rabbit,  an  additional diffuse band of M, 55,000-60,OOO was 
identified and presumably represents  the  intracellular portion, 
which has been cleaved from the receptor during generation of 
the GHBP. In  support of this,  the  intensity of the M, 55,000- 
60,000 band is markedly reduced when the liver was snap 
frozen in liquid N, (data not shown). Also, no such M, band  was 
observed in  preparations from rat, liver  where the  BP  is not 
receptor-derived (Fig. 3). However, a band at M, 35,00040,000 
was observed occasionally in some rat liver preparations  and 
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FIG. 4. Immunoprecipitation of GH receptor/BP and GHBP 
from nucleoplasm (A), 1% Triton X-100-solubilized outer nuclear 
membranes (B) ,  and 2% Triton  X-100-solubilized inner nuclear 
membranes (C). Immunoprecipitation was  achieved using mAb 263 
(open  squares) to precipitate GH receptoriBP and mAb 4.3 (closed dia- 
monds) to precipitate GHBP.  Bound and free hormone  were separated 
using the double antibody method as described  previously (30). Specific 
binding to GH receptoriBP was determined with 'T-hGH (approxi- 
mately 170,000 cpdtube) and recombinant bGH as displacing ligand (5 
pg/ml added). Specific binding was 2,  6.2, and 1.3%, respectively, and 
nonspecific binding was 4, 3.1, and 1.6%, respectively, of added radio- 
activity. The ordinates show precipitable binding as a percentage of 
mAb 263 precipitable specific binding. Points represent means of trip- 
licate determinations. Initial added concentrations of mAb 263 and 4.3 
at which maximum precipitation was obtained were  10  mg/ml and 250 
pg/ml,  respectively. Fractions were assayed at 1:2 dilution of that pre- 
pared as under "Experimental Procedures." Protein added was 420,850, 
and 530 pg for  nucleoplasm, 1% Triton  X-100-solubilized outer nuclear 
may represent a degradation product. 
Immunoprecipitation of Nuclear-associated GH Receptor and 
GHBP-GH binding activity was precipitable from nucleo- 
plasm, 1% Triton X-100-solubilized outer nuclear membrane 
and 2% Triton X-100-solubilized inner  nuclear  membrane  with 
two mAbs directed against the amino-terminal extracellular 
domain (mAbs 43  and 263) (Fig. 4, A X ) .  mAb 43  precipitated 
approximately 10% more total specific binding in  all fractions 
than mAb 263. To determine  whether both the full-length re- 
ceptor and GHBP were present in nucleoplasm, 1% Triton 
X-100-solubilized outer nuclear membranes, and 2% Triton 
X-100-solubilized inner  nuclear  membranes, we used a mono- 
clonal antibody  directed against  the 17-amino acid hydrophilic 
tail of the GHBP (mAb 4.3) and a polyclonal antisera  raised 
against recombinant rabbit receptor intracellular domain 
(ICAb). mAb 4.3-precipitable specific binding  was observed in 
all fractions  examined  (Fig. 4, AX) .   In  all cases, the maximum 
precipitation obtained with mAb 4.3 was less than  that ob- 
tained  with  either mAb 43 or 263. In nucleoplasm, 77%  of mAb 
263-precipitable specific binding was also mAb 4.3-precipi- 
table,  whereas  in 1 and 2% Triton X-100-solubilized outer  and 
inner  nuclear  membranes, only 40 and 43% precipitation, re- 
spectively, was observed (Fig. 4,A-C).  Full-length receptor was 
also  precipitable  from  nucleoplasm and solubilized inner  and 
outer  nuclear  membranes  with ICAb, whereas no precipitation 
was observed when  similarly treated  preimmune  rabbit  serum 
was  used at the  same protein  concentration  (Fig. 5, A-C). This 
was not due  to polyclonal antisera cross-reactivity  with homol- 
ogous regions of the lactogenic receptor as recombinant bGH 
was employed as displacing ligand  in  all immunoprecipitation 
experiments.  Immunoprecipitation of GH binding  activity  with 
mAb 4.3 and ICAb was  used to  determine  the  relative propor- 
tion of the GHBP and GH receptor in  the soluble nuclear frac- 
tions.  GHBP represented 80 2 6% of total GH binding  activity 
in nucleoplasm, 17 k 1% in 1% Triton X-100-solubilized outer 
nuclear  membranes,  and 5 k 3% in 2% Triton X-100-solubilized 
inner  nuclear  membranes. Based on the  assumption  that  all 
chromatin-associated GH binding activity was GH receptor 
(see below), the  outer  nuclear  membrane is the  primary  site of 
somatogenic lZ5I-hGH binding to receptor followed by inner 
nuclear  membrane  and  chromatin  with a small contribution 
from nucleoplasm (Fig.  6). According to immunoprecipitation 
with mAb 4.3, the  outer  nuclear  membrane is also the major 
site of binding to  the GHBP followed  by nucleoplasm and  the 
inner  nuclear  membrane (Fig. 6C). 
Immunolocalization of the Carboxyl %-minus  of the GH Re- 
ceptor in  Rat Liver Nuclei-We (22,  23) and  others (25) have 
previously shown that  the  amino  terminus of the receptor/BP 
and  the GHBP  (24) can be localized to  the nucleus by immu- 
nohistochemical techniques. To determine  whether  the  intra- 
cellular  domain of the GH receptor  was localized to  the nucleus, 
we used ICAb to detect the presence of the  intracellular domain 
in nuclei isolated  from rabbit liver. A band at M, 120,000  was 
detected in  rabbit liver  nuclei, and  the  intensity of this  band 
was  increased upon  prior  injection (10 min) of the  animal  with 
bGH (Fig. 30). The level of GH receptor in  membrane prepa- 
rations from GH-injected animals  was  not significantly differ- 
ent from noninjected animals. A similar phenomenon was ob- 
served for chromatin  prepared from rabbit liver  nuclei of GH 
injected and noninjected animals.  Thus a nuclear  translocation 
of the receptor was observed (see below). We also demonstrated 
the full-length  receptor in  preparations of rat liver and chro- 
matin. We also used immunohistochemistry to verify the pres- 
ence of the full-length GH receptor in  the  rat liver  nucleus. 
membranes, and 2% Triton  X-100-solubilized inner nuclear mem- 
branes, respectively. 
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FIG. 5. Immunoprecipitation of the GH receptor  from  nucleo- 
plasm (A), 1% Triton X-100-solubilized outer nuclear mem- 
branes (C) with  polyclonal  antisera (ICAb) raised  against 
branes (B) ,  and 2% Triton X-100-solubilized  inner  nuclear  mem- 
recombinant  intracellular  domain  protein. Specific binding to GH 
receptor was determined with lZ5I-hGH (approximately 200,000 cpml 
tube) and recombinant bGH as displacing ligand (5 pg/ml added). Am- 
monium sulfate precipitated preimmune rabbit serum at  the same pro- 
tein concentration served as control.  Specific binding was 0.8, 8.7, and 
4.2%, respectively, and nonspecific binding was 2.5, 2.2, and 1.5%, re- 
licate determinations. Initial concentration of ICAb was 10 mg/ml. Frac- 
spectively, of total radioactivity added. Points represent means of trip- 
tions were assayed at a 12 dilution of original fraction as described 
under "Experimental Procedures."  Respective protein added was 420, 
850, and 530 pg for nucleoplasm, 1% Triton X-100-solubilized outer 
nuclear membranes, and 2% Triton X-100 solubilized inner nuclear 
membranes, respectively. 
ICAb immunoreactivity was nucleocytoplasmic as described 
previously for the  extracellular egion of the receptor (data  not 
shown). ICAb immunoreactivity was abolished by preincuba- 
tion  (24 h at 4 "C) with excess recombinant  receptor intracel- 
lular domain, not by excess glutathione  S-transferase,  and no 
immunoreactivity was observed when similarly treated preim- 
mune  rabbit  serum  was  used at the  same protein  concentration 
instead of ICAb (see below for immunohistochemical controls). 
Affinity Cross-link of lZ5Z-hGH to Chromatin-Repeated at- 
tempts  to cross-link lZ5I-hGH to rat liver chromatin were not 
successful, most probably due  to  the low receptor number  in rat 
liver and also low nuclear capacity. To further  demonstrate  that 
the full-length  receptor was associated  with chromatin  in  rat 
liver (in  addition to Western blot analysis), we iodinated ICAb 
and performed binding  assays  (data  not shown). lZ5I-ICAb ind- 
ing to  chromatin  was specifically displaced by unlabeled ICAb 
but  not by similarly treated  normal  rabbit  serum at the  same 
protein concentration. We resorted  to  the  use of cell lines  trans- 
fected with  the full-length receptor or GHBP to definitively 
determine which GH binding moiety was anchored in  the  nu- 
cleus  (see below). 
Hormone Binding to GH Receptor and GHBP  cDNA-trans- 
fected  CHO and BRL Cell Nuclei-To determine  whether  the 
full-length receptor alone (in distinction to the physiological 
situation where the receptor and BP are co-expressed) was 
associated with  the nucleus, we subjected  purified  nuclei  from 
cell lines  stably  transfected  with  the full-length  receptor cDNA 
to binding analysis. Nuclei isolated from parental untrans- 
fected cells were used as specificity controls. Whole Nonidet 
P-40-washed  nuclei from CHO-638 cells subjected to  Scatchard 
analysis exhibited specific high affinity (K, = 1.3 -c 0.2 x lo9 "'1 
binding of lZ5I-hGH, whereas  the  untransfected  parental cell 
line,  when  assayed at the  same DNA concentration, did not 
(Fig. 7A). Low capacity specific binding could be detected in 
CHO cells at higher DNA concentrations but never to  the  same 
extent as CHO-638 cells. Since the  characterization of the rat 
nuclear GH receptor and binding  protein was performed with 
hepatic nuclei, we also  examined a rat liver cell line  transfected 
with  the full-length  receptor (BRL-638) and  the  parental cell 
line for nuclear binding of lZ5I-hGH. Again, specific high affinity 
(K, = 1.2 f 0.2 x lo9 M - ~ )  binding  was detected in  the nuclei of 
the receptor-transfected cells but  not  the  untransfected  paren- 
tal cell line (Fig.  7B). To determine which portion of the recep- 
tor  was responsible for nuclear anchorage, we examined the 
binding of lZ5I-hGH to whole nuclei isolated from CHO cells 
expressing the full-length  receptor, the GHBP  containing the 
17-amino acid hydrophilic tail (BP-21, a receptor in which 184 
amino  acids had been  deleted from the carboxyl-terminal in- 
tracellular domain (CHO-454) and a receptor  containing only 5 
of 349 amino  acids in  the  intracellular domain (CHO-294). Nu- 
clear  binding above the level of the  untransfected  parental cell 
line  in Nonidet  P-40-washed  nuclei was detected only in CHO- 
638  and CHO-454 cells (Fig. 8A), suggesting  that amino  acids 
295-454 of the receptor are necessary for nuclear anchorage. 
This observation was  not  due  to  membrane contamination as 
the CHO-294 cells express a membrane-bound receptor that 
was not anchored in the nucleus (Fig. 8B). The absence of 
membrane contamination in  these nuclei was also confirmed by 
lack of NADPH-cytochrome c reductase activity and by electron 
microscopy (Fig. 8C). 
GH Znduced Nuclear Danslocation of the GH Receptor-We 
also  performed  immunocytochemistry on CHO-638 cells grown 
in 10% fetal calf serum  to localize the GH receptor to  the  nu- 
cleus. Immunodetection of antigen  in CHO-638 cells with ICAb 
revealed  both nuclear  and cytoplasmic localization of the  re- 
ceptor intracellular region (Fig. 9A ). ICAb immunoreactivity 
Nuclear  Danslocation of GH Receptor 31741 
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FIG. 6. Relative  subnuclear GH binding  activity (panel A), GH 
receptor (panel B ) ,  and  GHBP (panel C) content  in  adult  female 
rat  liver. Outer nuclear membranes ( O N M )  were  solubilized with 1% 
Triton X-100; inner nuclear nuclear membranes (ZNM) were  solubilized 
with 2% Triton X-100 and chromatin (C) constituted 2% Triton X-100- 
insoluble material. Nucleoplasm (N) was formed by homogenization of 
whole  nuclei. GH receptor number in soluble fractions was estimated 
with the inclusion of ICAb at a final concentration of 1 pg/ml and 
precipitation with protein G-Sepharose. GHBP number in soluble frac- 
tions was estimated with the inclusion of  mAb 4.3 at a final concentra- 
tion of 0.24  pg/ml, and precipitation with the double antibody method as 
described under “Experimental Procedures.” T - h G H  with recombi- 
cross-hatched portion of the columns in panel A represent PEG  6,000- 
nant bGH as displacing ligand were used  for data presented herein. The 
soluble  specific binding, and the black portion represents PEG  6,000- 
precipitable specific binding. For calculations in panels B and C, it is 
assumed that all chromatin-associated GH binding activity is full- 
length receptor. 
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FIG. 7. Appearance  of  nuclear GH binding  in cells stably  trans- 
fected  with cDNA encoding  the  full-length  rat GH receptor. A, 
hormone competition analysis of 9 - h G H  binding to nuclei isolated 
from  CHO and CHO-638 (stably transfected with GH receptor cDNA) 
(open  squares ). Nuclei  were prepared as described under “Experimental 
Procedures” and washed with 0.4%  Nonidet P-40. Specific binding was 
determined with 9 - h G H  with hGH as displacing ligand. Nuclei  were 
assayed at a final DNA concentration of  20 pg/ml. The specific activity 
of lZ5I-hGH was 153 pCi/pg of protein, and  total added radioactivity was 
107,000 cpdtube. Data  are representative of four experiments, and 
B, hormone  competition analysis of lZ6I-hGH binding to nuclei isolated 
results are expressed as mean f S.E. The average K, was 1.3 x lo9 M-’. 
from BRL and BRL-638 (stably transfected with GH receptor cDNA) 
(open  squares) with hGH as displacing ligand. Nuclei  were prepared as 
Nonidet  P-40.  Specific binding was determined with lZ6I-hGH with hGH 
described under “Experimental Procedures” and washed with 0.4% 
pg DNMml. The specific activity of  “‘I-hGH was 153 pCi/pg and total 
as displacing ligand. Nuclei  were assayed at a final concentration of  20 
added radioactivity was 125,000 cpdtube. Data are representative of 
four experiments, and  results  are xpressed as mean k S.E. The average 
K, was 1.2 k 0.2 x lo9 M-’. 
was abolished by preincubation (24 h at 4 “ C )  with excess re- 
combinant  receptor intracellular domain, but  not by excess glu- 
tathione  S-transferase  or recombinant GHBP, and no immuno- 
reactivity was observed when similarly treated preimmune 
rabbit  serum  was  used at the  same protein  concentration in- 
stead of ICAb (Fig. 9, B-E). To determine if GH affected the 
intracellular  distribution of the GH receptor, we then incubated 
CHO-638 cells in serum-free  media for 12 h before administra- 
tion of GH. Cells incubated  in  serum-free media still possessed 
a nuclear receptor (as predicted from the above binding  data), 
but  the  intensity of the  nuclear immunoreactivity  was  reduced 
(Fig. 1OA). Also in  these cells there  was a prominent  and diffuse 
cytoplasmic distribution of the receptor. Within 5-10 min  after 
administration,  GH induced a clearly defined rearrangement of 
the  intracellular  distribution of the GH receptor  whereby nu- 
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FIG. 8. Requirement  of the intracel lular   domain  of  the GH re- 
ceptor for   nuclear  anchorage. A,  specific binding of '""I-hGH to 
nuclei isolated from stably  transfected CHO cells expressing  the  GH 
receptor,  carboxyl-terminal  truncations of the receptor,  and  the GHBP. 
Nuclei were prepared as  described under "Experimental Procedures" 
and  washed  with 0.4% Nonidet P-40. Specific binding  was  determined 
with Iz5I-hGH and 5 pg/ml added hGH as displacing ligand and  are 
expressed a s   c p d p g  DNA. The specific activity of "'I-hGH was  122 
pCi/pg, and  total  added  radioactivity  was  180,000 cpdtube.  Data  are 
representative of five experiments,  and  results  are  expressed  as  mean 
S.E. B,  ratio of nuclear  to  total  cellular  binding  in CHO cells stably 
clear  immunoreactivity was  augmented at  the expense of cyto- 
plasmic  immunoreactivity  (Fig. 1OB). This  event was rapid  and 
transient  as by 1 h after  GH  administration,  the  intracellular 
distribution of the receptor  more closely resembled that of se- 
rum-deprived cells (Fig. 1OC). Similar rapid translocation of 
the  GH receptor was observed in BRL-638, although  in  these 
cells nuclear immunoreactivity was more  prominent in quies- 
cent cells and  thus  the observation of translocation  was more 
difficult (Fig. 10, D andE).  Thus GH was able to induce  nuclear 
translocation of its receptor. Translocation  was  not observed if 
the cells were cultured in serum-containing media for more 
than 24  h after passaging. 
DISCUSSION 
We report  here  that both the GH receptor and  the GHBP are 
localized to  and associated with  the nucleus in  rat liver. More- 
over in cDNA-transfected cells expressing GH receptor, nuclear 
GH receptor is also demonstrable  and nonmembrane  nuclear 
anchorage of the GH receptor requires  the presence of at  least 
the  first half of the  intracellular domain. That  the carboxyl 
terminus of the GH receptor is  present  in  the nucleus and  is 
required for nuclear anchorage has been established by several 
criteria: ( a )  immunochemical detection of the carboxyl-termi- 
nal domain of the GH receptor in  the nucleus  with polyclonal 
antisera directed against recombinant intracellular domain 
protein; ( b )  precipitation of GH binding  activity from solubi- 
lized outer and inner nuclear membranes with antisera di- 
rected against  the receptor intracellular domain (ICAb); (c) the 
appearance of nuclear binding sites for lz5I-hGH in cell lines 
transfected with full-length  receptor  cDNAbut  not the  parental 
lineage; ( d )  loss of nuclear anchorage of the receptor in cells 
that express a receptor containing only 5 of 349 amino  acids  in 
the  intracellular domain; and ( e )  retention of nuclear anchor- 
age of the receptor in cells that express a receptor in which only 
184 amino acids have been deleted from the carboxyl-terminal 
intracellular domain. 
The functional significance of a nuclear growth hormone re- 
ceptor is not yet  apparent.  That  the full-length  receptor medi- 
ates GH-induced events (6, 4749)  and  that  this moiety is also 
in  the nucleus suggests some function. It  is  interesting  that 
some of the  demonstrated potential intermediaries  in GH sig- 
nal  transduction  such as protein kinase C (401, MAP kinases, 
and S6 kinases  (17)  are also localized to  the nucleus. In  the case 
of MAP kinase,  although  present  in  the nucleus in  the quies- 
cent state, it undergoes translocation to the nucleus upon 
stimulation  with phorbol esters,  serum,  and growth  factors (18, 
50). During  preparation of this work it was also shown that GH 
induces the nuclear translocation of MAP kinase (51). It  is 
interesting that the GH-inducible nuclear factor (GHINF), 
which interacts  with  the  Spi 2.1 promoter, is not dependent on 
de novo synthesis of protein (49, 52). Indeed, GH-inducible 
nuclear factor is subject to phosphorylation-dependent  nuclear 
translocation  (49,531 similar  to  the  interferon y-stimulated  p91 
(STAT 1) (54). p91  has recently been reported to directly asso- 
ciate with the interferon y receptor (55). It  is possible that 
GH-inducible nuclear factor associates directly with the GH 
receptor and  the two molecules tandemly translocate to the 
transfected  with cDNA encoding the  GH  receptor  and  receptor  mutants 
containing carboxyl-terminal deletions. Nuclei were prepared as  de- 
scribed  under  "Experimental  Procedures"  and  washed  with 0.4% Non- 
idet P-40. Nuclear  and  total  cellular  binding  were  determined by the 
binding of Iz5I-hGH and 5 pg/ml added  hGH as  displacing  ligand.  The 
specific activity of '*'I-hGH was  122 pCi/pg, and  total  added radioac- 
tivity  was 180,000 cpdtube.  Data  are  representative of three  experi- 
ments,  and  results  are  expressed  as  mean r S.E. C, electron  micrograph 
of nuclei isolated from CHO-255 cells for demonstration of nuclear 
punty. 
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ficity of ICAh used  to  detect GH re- 
FIG. 9. Immunocytochemical speci- 
ceptor  intracellular  domain  in GIf re- 
ceptor cDNA transfected  cells (CHO- 
638). Thr  (;H recrptor was drtrcted  with 
hinant  receptor  intracellular  domain  and 
pt~lyclonal  antisera  raised  against  recom- 
use of the hiotin-streptavidin-horse rad- 
ish  peroxidase  technique (22)  as descrihrd 
under  "Experimental  Procedures." A,  
ICAh  immunoreactivity  in  CHO-638  cells 
cultured  in  the  presence of 10"; frtal calf 
serum. Note the presence of both cyto- 
plasmic  and  nuclear  immunoreactivity. n, 
lack of cellular  immunoreactivity  in  CHO- 
638 cells  cultured  in  the  presence of 109 
fetal  calf  serum  when  ammonium  sulfate- 
precipitated  normal  rahhit  serum  was 
used as primary  antibody. C ,  loss of ICAh 
immunoreactivity in CfIO-638 cells cul- 
tured  in  the  presence of lor+ fetal  calf  se- 
rum  when  ICAh  was  preincuhated  in  the 
presence of 20 p g h l  of purified  recomhi- 
nant rrceptor intracellular domain pro- 
tein (24 h a t  4 "C). D, retention of ICAh 
immunoreactivity in CHO-638 cells cul- 
tured in the  presence of 10'; fetal  calf  se- 
rum  when ICAh was  preincuhated  in  the 
presrnce of 20 p g h l  of purified  recomhi- 
4 "C). E ,  retention of ICAh  immunoreac- 
nant glutathione S-transferase (24 h a t  
tivity in CHO-638 cells cultured in the 
presence of 10"; fetal calf serum when 
ICAh was  preincuhated  in  the  presence of 
20 p g h l  of purified  rrcomhinant  rat  GH 
hinding  protein (2.1 h a t  4 "C). 
ai 
nucleus. We have, at present, no experimental evidence that 
the GH receptor participates in the transcription complex. 
Whether  the  nuclear  translocation of M A P  kinase is also ac- 
companied by nuclear translocation of the GH receptor (and 
other  associated  molecules  such as JAK-2)  and  what  role  the 
internalization of GH  plays  in  this  process  remain  to  be  deter- 
mined.  Indeed  both  MAP  kinase  and  the  GH  receptor  translo- 
cate  to  the  nucleus  in  a  similar  time  frame,  and M A P  kinase 
has  been  reported  to  directly  associate  with  growth  factor  re- 
ceptors ( 5 6 ) .  That  free  binding sites for GH  exist  in  the  nucleus, 
MAP kinase is nuclear  in  the  quiescent cell (17), and ,JAK2 is 
localized  in the  nucleus2  suggests  that  ligand  activation is not 
ahsolutely  necessary  for  nuclear  localization.  However,  the re- 
ported nuclear translocation of GH-inducible nuclear factor 
and  other STAT proteins  would  presumably  preclude  cytoplas- 
mic  independent  transcription.  However,  one of the STAT pro- 
teins  activated by PRL is localized to  the  nucleus  in  the  quies- 
cent  state (57).' In  this  regard, i t  is  also  interesting  to  note  that 
PRL is capable of stimulation of protein  kinase C activity  in 
purified  nuclei  from  intact  male  rat  liver (40) and  that  PRL  can 
also induce  RNA  synthesis  from  isolated  nuclei (16). PRL  has 
also been  demonstrated  to  possess a nuclear  receptor (11). 
' P. E. Lnhie. T. , J .  J. Wood. L.-A. Haldosh,   and G .  Norstedt.  unpuh- 
lished  observations. 
The  GHRP  in  the  mouse  and  rat is produced :IS a  separatr 
transcript (3,s) and is found a s  a  soluhle  protrin in serum i29). 
However, the  alternativrly  splicrd  GHRP  can  also  hr  immuno- 
histochemically localized to  thr  nuclrus  and  cytoplasm of mul- 
tiple cell types (241 in  tissues  that  rxpress  thr  1.2-kilohasr RNA 
species (58). Furthermorr, Frick and Goodman (591 havr rr- 
cently  reported  that  the  GHRP is found  in association ui th  t h r  
microsomal fraction of adipocytrs. Although wr find soluhlr 
GHRP in the nucleoplasm of rat  hepatocytrs, Fvr ;11so rrpnrt 
here  that  thr  GHRP is associated with intracrllular mrm- 
branes  that  include  the  microsomal  fraction  and  thr  innrr  and 
outer  nuclear  memhrancs. How thr   GHRP is trthrred  to  thrsr 
membranes  remains  to be detrrminrd.  The  intracrllular rolr of 
the GHBP is unknown but appears not to invnlvr positivr 
events  in  GH signal transduction  as  nrithrr MAP kinasr  nor 
mitogenicity is GH-stirnulatrd in cells transfrctrd with thr 
GHRP (6), although  such  GH  effects arr ohsrnvrd in rrcrptor- 
transfected cells. The nuclear GFIRP may compete with the 
nuclear  GH  receptor for free  ligand in a manner  similar  to  that 
reported for the GHRP in  the  extracellular  spacr ffi0,. Similarly 
the  GHRP  may  compete  with  thr  rrcrptor for othrr  protrins 
tha t  bind the  extracellular  rrgion ( 5 9 ,  therrhy also modulating 
the  potential  responsr  to  GH.  The  GHRP in isolation  docs not 
appear  capable of nonmemhrane  nuclrar  anchorage.  Howrver 
31744 
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GH receptor in cultured cells. The GH receptor was detected with polyclonal antisera (ICAb) raised against recombinant receptor intracellular 
Fro. 10. Immunocyt ____-___~n 0- -____ I.-asL”-nted GH receptor  and ligand-induced  nuclear  translocation of the 
domain and use of the biotin-streptavivdin-horse radish peroxidase technique (22) as described under “Experimental Procedures.” A, ICAb 
immunoreactivity in CHO-638 cells cultured in serum-free media.  Note the predominantly cytoplasmic and relative paucity of nuclear immuno- 
reactivity. E,  ICAb immunoreactivity in CHO-638 cells cultured in serum-free media but treated for 5 min with 100 m hGH. Note the shift of 
cytoplasmic immunoreactivity to the nuclear compartment. C, ICAb immunoreactivity in CHO-638  cells cultured in serum-free media and  treated 
for 60 min with 100 m hGH. Note that the intracellular distribution of the GH receptor is similar to that of cells in A. D,  ICAb immunoreactivity 
in BRL638 cells cultured in serum free media. E, ICAb immunoreactivity in  BRL638 cells cultured in serum-free media but  treated for 5 min with 
100 m hGH. Note the shift of cytoplasmic immunoreactivity to the nuclear compartment. 
we cannot exclude that  the nuclear GH receptor and GHBP tion of similarly treated preimmune rabbit serum, and  the ob- 
may form a heterodimer with GH, thereby anchoring the servation was repeatable with different nuclear preparations. 
GHBP in  the nucleus. “he GHBP has previously  been  demon- That  the full-length receptor is associated with nonmembra- 
strated to form a trimer with one molecule of GH (61,62). nous components of the nucleus suggests that  the receptor is 
It is interesting that we are able to precipitate soluble GH not obligated to be  membrane-bound. The soluble GH receptor 
binding activity from  nucleoplasm with the antibody directed binding activity may therefore represent partially proteolyzed 
against the intracellular domain (ICAb) as  the full-length re- or  mechanically sheared (from  homogenization)  receptor that 
ceptor is considered to be membrane associated (1,2). No such retains sufficient intracellular domain to allow precipitation. 
precipitation was observed with the same protein concentra- Nevertheless it has been reported that  the whole functional 
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insulin receptor exists as a soluble form  (63) and  that  the epi- 
dermal  growth factor  receptor  associates with cytoskeletal el- 
ements (64). Whether  the  nuclear associated  receptor adopts a 
conformation  different to  that of the membrane-associated re- 
ceptor is not known, but  our  studies (23) on the  rabbit  liver 
chromatin  GH receptor demonstrate differential spatial access 
of one mAb (mAb 7)  to  the hormone  binding site between the 
chromatin  and microsomal receptor. 
The association of the GH receptor and GHBP with  the  nu- 
cleus  implies that a specific nuclear  transport mechanism for 
these  proteins  must  exist (65). Such specific nuclear  transport 
is thought to  be mediated by nuclear localization sequences 
(NLSs)  (65, 66). Since the  extracellular domain of the receptor 
is common to  both  GH  binding moieties, a NLS might be ex- 
pected to therein exist. However a search for primary se- 
quences in  the  extracellular domain of the GH receptor homol- 
ogous to known NLS was  not  fruitful.  This not  surprising, as 
no single  consensus  sequence for nuclear localization has 
emerged  (66), and  proteins  that  have  had  their  nuclear  target- 
ing sequence  deleted can still be  transported  into  the nucleus 
as part of a complex with a  protein that  has a nuclear  targeting 
sequence (66). Also in  the case of the GHBP (M, 55,000), the 
association with  the  nucleus may be simply passive as non- 
nuclear  proteins  smaller  that 40-60 kDa  (67)  often equilibrate 
between the nucleus and cytoplasm. However a molecule the 
size of the  GH receptor requires specific transport across the 
nuclear pore complex (67). That  the receptor  associates with 
the nucleus in  the absence of ligand  indicates  the presence of a 
constitutive karyophilic signal  such as exists  in  the progester- 
one and glucocorticoid receptors  (68, 69). Presumably,  deletion 
of the constitutive signal would result  in  an  entirely cytoplas- 
mic compartmentalization  but  the receptor would still undergo 
ligand  dependent  nuclear translocation.  Site-directed mu- 
tagenesis of the receptor to  identify potential NLSs should be 
useful in  this  regard. 
We have  presented  the  first  demonstration f ligand-depend- 
ent  nuclear  translocation of the GH receptor although  this phe- 
nomenom has been  reported for insulin  (19,20)  and  epidermal 
growth  factor  (21) receptors  and  is well documented for steroid 
receptors (9). Similarly  the PRL receptor has been  reported to 
translocate to the nuclear periphery upon stimulation with 
interleukin 2  (70). The  nuclear  translocation of the GH receptor 
occurs in  the  same  rapid  time  frame as that reported for the 
glucocorticoid receptor  (69) as well as  transcription factors such 
as p91 (54). Interestingly  the  nuclear  translocation of the GH 
receptor and GH (28) are temporally distinct. Maximal nuclear 
translocation of the receptor occurs within  10  min,  whereas 1 h 
is  required for complete nuclear  saturation by GH. We specu- 
late  that  ligand binding at the cell surface could cause a  sub- 
population of receptor to  translocate  to  the nucleus in  the  un- 
liganded state. Receptor phosphorylation may be the  stimulus 
for translocation to  the nucleus. In  this  regard,  it  is  interesting 
that receptor and JAK-2 phosphorylation is maximal 5 min  and 
greatly diminished 60 min  after GH stimulation (7). This is 
identical  to  the  pattern  that we observe with ligand-induced 
nuclear translocation of the receptor in this study and the 
appearance of GH stimulated protein binding  to a gamma ac- 
tivated sequence-like element in the Spi 2.1 promotor (49). 
Thus, receptor  residency in  the nucleus  may be dependent on 
the phosphorylation state of the receptor or receptor-associated 
molecules. 
In conclusion, we report  that  although both the GH receptor 
and GHBP are nuclear-associated  proteins, the presence of the 
intracellular domain of the GH receptor is required for non- 
membrane  nuclear anchorage. Furthermore,  the GH receptor is 
subject to  ligand-dependent  nuclear translocation.  Several  im- 
portant facets of this association still  remain  to be determined 
(a) the mechanism  responsible for nuclear localization of the 
GH receptor/BP including  identification of potential NLSs; ( b )  
the mechanism  responsible for membrane  attachment of the 
GHBP; (c) the mechanism of ligand-induced nuclear transloca- 
tion;  and ( d )  the mechanism  whereby the GH receptor is  an- 
chored in  the nucleus, which includes characterization of re- 
ceptor-associated molecules. Most importantly however, it 
remains  to be demonstrated  that  the  nuclear GH receptor has 
a peculiar function pertaining to, or participates in, GH-in- 
duced signaling mechanisms that eventually leads to gene 
transcription or mitogenesis. 
anamid) for the generous giR of the recombinant rat GHBP and mAb 
Acknowledgments-We thank Dr. William Baumbach (American Cy- 
4.3. We thank Dr. J. Garcia-Aragon for help in production of the recom- 
binant receptor intracellular domain used for antisera generation. 
REFERENCES 
1. Leung, D. W., Spencer, S. A., Cachianes, G., Hammonds, R. G., Collins, C., 
Henzel, W. J., Barnard, R., Waters, M. J.,  and Wood, W. I. (1987) Nature 330, 
537-543 
2. Mathews, L. S., Enberg, B., and Norstedt, G. (1989) J. Biol. Chem. 264, 
99059910 
3. Smith, W. C., Kuniyoshi, J., and Talamantes, F. (1989) Mol. Endocrinol. 3, 
984-990 
4. Cosman, D., Lyman, S. D., Idzerda, R. L., Beckmann, M. P., Park, L. S., 
Goodwin, R. G., and  March,  C. J. (1990) Pends Biochem. Sci. 15,265-270 
5. Baumbach, W. R., Horner, D. L., and Logan, J. S. (1989) Genes & Deu. 3, 
1199-1205 
6. Moller, C., Hansson, A,, Enberg, B., Lobie, P. E., and Norstedt, G. (1992) 
7. Argetsinger, L. S., Campbell, G. S., Yang, X., Witthuhn, B. A,, Silvennoinen, O., 
J.  Bid. Chem. 267,23403-23408 
Ihle, J. N., and  Carter-%, C. (1993) Cell 74,237-244 
8. Van der Kuur,  J., Wang, X., Campbell, G., Billestrup, N., Norstedt, G.,  Zhang, 
L.-Y., Ihle, J. N., and Carter&, C. (1994) J.  Biol. Chem. in  press 
9. Beato, M. (1989) Cell 66,33@44 
J.  Biol. Chem. 263,2098-2103 
Putnam, C. W. (1992)Arch. Biochem.  Biophys. 296, 198-206 
Res. Commun. 119,220-227 
1269-1273 
Proc. Nutl.  Acad.  Sci. U. S. A. 83,372%3732 
F. (1987) Proc.  Natl.  Acad.  Sci. U. S. A. 84, 677M774 
56-63 
10. Vlgneri, R., Goldtine, I. D., Wong, K. Y., Smith, G. J.,  and Pezzino, V (1978) 
11. Buckley, A. R., Montgomery, D. W., Hendrix, M. J. C., Zukoski, C. F., and 
12. Re, R. N., Vizard, D. L., Brown, J., and  Bryan, S. E. (1984) Biochem.  Biophys. 
13. Yanker, B. A,, and Shooter, E. M. (1979) Proc. Natl. Acad. Sei. U. S. A. 76, 
14. Rakowicz-Szulcynska,  E. M., Rodeck, U., Herlyn, M., and Koprowski, H. (1986) 
15. Bouche, G., Gas, N., Prats, H., Baldin, V., Tauber, J. P., Teissie, J.,  andAlmaric, 
16. Chomczynski, P., and Topper, Y. J. (1974) Biochem.  Biophys. Res. Commun. 60, 
17. Chen, R.-H., Sarnecki, C., and  Blenis, J. (1992) Mol.  Cell. Bid. 12, 915-927 
18. Lenormand, P., Sardet, C . ,  Pages, G., L'Allemain, G., Brunet, A., and 
20. Podlecki, D. A,, Smith, R. M., Kao, M., %ai, M., Huecksteadt, T., Brandenburg, 
19. Smith, R. M., and  Jarret, L. (1987) Proc.  Nutl.  Acad.  Sci. U. S. A.  84,459-463 
D., Lasher, R. S., Jarret, L., and Olefsky, J. M. (1987) J.  Biol. Chem. 262, 
3362-3368 
Pouyssegur, J. (1993) J. Cell Biol. 122, 1079-1088 
21. Jiang, L.-W., and Schindler, M. (1990) J. Cell Bid. 110, 559-568 
22. Lobie, P. E.,  Breipohl, W., and  Waters, M. J. (1990) Endocrinology 126, 299- 
23. Lobie, P. E.,  Barnard, R., and  Waters, M. J. (1991) J. Biol. Chem. 266,22645- 
306 
22652 
24. Lobie, P. E., Garcia-Aragon, J., Wang, B. S., Baumbach, W. R., and  Waters, M. 
"." 
J. (1992) Endocrinolom 130.3057-3065 
25. Fraser, R. A,, and  Harvey S. (1992) Endocrinology 130, 3593-3600 
26. Spencer, S. A,, Hammonds, R. G., Henzel, W. J., Rodriguez, H.,  Waters, M. J., 
27. Sotiropoulos, A., Goujon, L., Simonin, G., Kelly, P. A,, Postel-Vinay, M.-C., and 
28. Lobie, P. E., Mertani, H., Morel, G., Morales-Bustos, O., Norstedt, G., and 
29. Sadeghi, H., Wang, B. S., Lumanglas, A. L., Logan, J. S., and  Baumbach, W. R. 
30. Barnard, R., Bundesen, P. G.,  Rylatt, D. B., and  Waters, M. J. (1985) Biochem. 
31. Barnard, R., and  Waters, M. J. (1986) Biochem. J.  237,885-892 
32. Barnard, R., Bundesen, P. G., Rylatt, D. B., and Waters, M. J. (1985) 
33. Smith, D. B., and  Johnson, K. S. (1988) Gene (Amst.)  67,  31-40 
35. Laemmli, U. K. (1970) Nature 227, 680-685 
34. Bradford, M. (1976) Anal.  Biochem. 72,248-254 
36. Francis, S. M., Enerback, S., Moller, C.,  Enberg, B., and  Norstedt, G. (1993) 
37. Labarca, C., and  Paigen, K. (1980) Anal.  Biochem. 102, 344-352 
38. Lowry, 0. H.,  Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J.  Bid. 
and Wood, W. I. (1988) J. Biol. Chem. 263, 7862-7867 
Finidori, J. (1993) Endocrinology 132, 1863-1865 
Waters, M. J. (1994) J. Biol. Chem. 269, 21330-21339 
(1990) Mol. Endocrinol. 1799-1805 
J. 231, 459468 
Endocrinology 115, 1805-1813 
Mol. Endocrinol. 7, 972-978 
Chem. 193,265-275 
31746 Nuclear  Dansloc tion of GH Receptor 
39. Salacinski, P. R. P., McLean, C., Sykes, J. E. C., Clement-Jones, V.  V., and 
40.  Buckley, A. R.,  Crowe, P. D., and Haddock-Russell, D.  (1988) Proc. Natl. Acad. 
41.  Wang, T. Y. (1967) Methods Enzyrnol. 12, 417421 
42. Burwen, S. J., and Jones, A. L. (1987) l h n d s  Biochern. Sci. 12, 159-162 
43. de Duve, C., Pressman, B.  C., Gianetto, R., Wattiaux, R., and Appelmans, F. 
44. Waters, M. J., and Friesen, H. G. (1979) J. Biol.  Chem. 254, 6815-6825 
45. Scatchard, G.  (1949) Ann.  NYAcad. Sei 51, 660-672 
46. Macpherson, G. A. (1985) J. Pharmacol.  Methods 14, 213-218 
47. Billestrup, N., Moldrup, A,, Serup, P., Mathews, L. S., Norstedt, G., and 
48. Emtner, M., Mathews, L. S. ,  and Norstedt, G. (1990) Mol. Endocrinol. 4, 
Nielsen, J. H. (1990) Proc. Natl. Acad.  Sci. U. S. A.  87, 7210-7214 
2014-2020 
49. Sliva, D.,  Wood, T. J., Schindler, C.,  Lobie, P. E., and Norstedt, G. (1994) J. Biol. 
50. Gonzalez, F.  A., Seth, A,, Raden, D. L., Bowman,  D. S., Fay, F. S. ,  and Davis, R. 
Chern. 269,26208-26214 
51.  Gronowski, A. M., and Rotwein, P. (1994) J. Biol. Chem. 269,  7874-7878 
J. (1993) J. Cell Biol. 122, 108%1101 
52. Yoon, J.-B., Berry, S. A,, Seelig, S., and  lbwle, H. C. (1990) J. Biol. Chem. 265, 
19947-19954 
53.  Finbloom, D. S. ,  Petricoin, E. F., Hackett, R.  H.,  David,  M., Feldman, G. M., 
Igarashi, K.-I., Fibach, E.,  Weber, M. J., Thorner, M. O., Silva, C.  M., and 
Lamer, A. C. (1994) Mol. Cell. Biol. 14, 2113-2118 
Lowry, P. J. (1981) Anal. Biochern. 117,13&142 
Sci. U. S. A.  85,8649-8653 
(1955) Biochem. J. 60,604-617 
54. Pellegrini, S., and Schindler, C. (1993) %rids Biochem. Sci. 18,338-342 
55. Greenlund, A. C., Farrar, M. A,, Vlviano, B. L., and Schreiber, R. D. (1994) 
56. Volonte, C., Angelastro, J. M., and Greene, L. A. (1993) J. Biol. Chem. 268, 
57. Happ, B., and Groner, B. (1993) J.  Steroid Biochern. Mol. B i d .  47,  21-30 
58. Carlsson, B., Billig, H., Rymo, L., and Isaksson, 0. G. P. (1990) Mol. Cell. 
59. Frick, G. P., and Goodman,  H. M. (1992) Endocrinology 131,3083-3090 
60.  Lim,  L., Spencer, S .  A.,  McKay,  P., and Waters, M. J. (1990)Endocrinology 127, 
61. De  Vos,  A.  M., Ultsch, M., and Kossiakoff, A. A. (1992) Science 255,306-312 
62. Cunningham, B.  C., Ultsch, M.,  DeVos,  A.  M., Mulkemn, M. G., Clauser, K R., 
63. Papa, V., Russo, P., Gliozzo, B., Goldfine, I.D., Vigneri, R., and Pezzino, V. 
64. den Hartigh, J. C., van Bergen en Henegouwen, P. M. P., Verkleij, A. J., and 
65. Silver, P. A. (1991) Cell 64,489497 
66. Dingwall, C., and Laskey, R. A. (1991) Dends Biochern. Sci. 16,478-481 
67. Peters, R. (1986) Biochim.  Biophys.  Acta 864, 305-359 
68.  Guiochon-Mantel,  A,,  Loosfelt, H., Lescop,  P., Sar, S. ,  Atger, M., Perrot- 
69. Picard, D., and Yamamoto, K. R. (1987) EMBO J. 6,3333-3340 
70.  Clevenger, C. V., Russell, D. H., Appasamy, P. M., and Prystowsky, M.  B. (1990) 
EMBO J.  13, 1591-1600 
21410-21415 
Endocrinol. 73, Rl-R6 
1287-1291 
and Wells, J. A. (1991) Science 254, 821-825 
(1993) Endocrinology 133, 1369-1376 
Boonstra, J. (1992) J. Cell Biol. 119,34%355 
Applanat, M., and Milgrom, E. (1989) Cell 57,  1147-1154 
Proc. Natl.  Acad.  Sci. U. S. A. 87, 6460-6464 
